Loading...
XSTO
XVIVO
Market cap981mUSD
Jun 16, Last price  
295.60SEK
1D
-0.87%
1Q
-29.03%
Jan 2017
235.91%
IPO
1,341.95%
Name

Xvivo Perfusion AB

Chart & Performance

D1W1MN
P/E
54.08
P/S
11.32
EPS
5.47
Div Yield, %
Shrs. gr., 5y
3.39%
Rev. gr., 5y
30.08%
Revenues
822m
+37.63%
14,724,00068,922,00084,702,000120,245,000138,177,000148,342,000187,868,000220,838,000179,861,000258,386,000415,292,000597,542,000822,415,000
Net income
172m
+87.52%
-769,0008,054,0003,738,0005,131,0001,501,0006,260,00012,685,0004,939,000-43,735,0008,152,00018,427,00091,820,000172,182,000
CFO
111m
+140.43%
1,669,00013,464,000-3,741,0008,578,00012,550,00022,190,00023,627,00029,505,000-12,266,000-12,059,00027,856,00046,287,000111,290,000
Earnings
Jul 10, 2025

Profile

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
IPO date
Oct 08, 2012
Employees
142
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
822,415
37.63%
597,542
43.88%
415,292
60.73%
Cost of revenue
734,099
597,578
411,056
Unusual Expense (Income)
NOPBT
88,316
(36)
4,236
NOPBT Margin
10.74%
1.02%
Operating Taxes
27,766
2,701
3,887
Tax Rate
31.44%
91.76%
NOPAT
60,550
(2,737)
349
Net income
172,182
87.52%
91,820
398.29%
18,427
126.04%
Dividends
Dividend yield
Proceeds from repurchase of equity
429,250
447
BB yield
-4.35%
-0.01%
Debt
Debt current
10,268
5,550
Long-term debt
52,606
14,460
Deferred revenue
Other long-term liabilities
68,455
65,616
137,831
Net debt
(415,521)
(483,796)
(226,946)
Cash flow
Cash from operating activities
111,290
46,287
27,856
CAPEX
(43,015)
(130,946)
Cash from investing activities
(243,814)
(161,619)
(197,624)
Cash from financing activities
(10,902)
418,547
(6,842)
FCF
(43,011)
(129,061)
(64,034)
Balance
Cash
415,521
546,088
246,545
Long term investments
582
411
Excess cash
374,400
516,793
226,191
Stockholders' equity
292,561
181,263
116,297
Invested Capital
1,932,672
1,860,835
1,460,391
ROIC
3.19%
0.02%
ROCE
3.97%
0.26%
EV
Common stock shares outstanding
31,668
29,935
29,526
Price
489.00
48.41%
329.50
80.05%
183.00
-34.29%
Market cap
15,485,638
57.00%
9,863,631
82.55%
5,403,248
-32.95%
EV
15,070,117
9,379,835
5,176,302
EBITDA
88,316
30,827
46,403
EV/EBITDA
170.64
304.27
111.55
Interest
1,190
605
Interest/NOPBT
14.28%